Medically Reviewed by Dr. Michael Nguyen, PharmD, BSPharm — Functional Medicine Pharmacist, Sterile Compounding Specialist, PCCA & NHIA Certified. 27+ years of clinical experience in peptide therapy and metabolic health.
Key Takeaways
- › Peptides are short chains of amino acids, usually fewer than 50, that work as signaling molecules. They tell cells what to do rather than blocking a receptor the way most small-molecule drugs do.
- › Nearly every therapeutic peptide is injected subcutaneously because digestive enzymes destroy them. Even oral semaglutide, engineered with an absorption enhancer, reaches only about 1% bioavailability.
- › The six practical categories are repair, growth hormone secretagogues, metabolic, mitochondrial, cognitive, and immune. Timelines to notice change range from about two weeks to six months depending on the category.
- › Start one peptide at a time. Running two new compounds together makes it impossible to know which one produced the benefit or the side effect.
- › Human trial data is genuinely thin for most peptides. Some of that is a funding gap on unpatentable molecules, but at least one peptide ran a real human obesity trial and failed to beat placebo.
Most people arrive at peptide therapy sideways. A friend mentions BPC-157 for a stubborn tendon, a podcast covers mitochondrial peptides, or a GLP-1 conversation drifts into what else is out there. What follows is usually a week of contradictory forum posts and a vial of powder nobody explained how to mix.
This guide is the foundation. It covers what peptides actually are at a molecular level, why they behave differently from both hormones and conventional drugs, the six categories worth knowing, how they’re administered and stored, what realistic timelines look like, how to sequence a first protocol, and which baseline labs are worth running. It also treats the evidence honestly, including where the human data is thin and where a trial ran and came up empty.
What Is a Peptide, Exactly?
A peptide is a short chain of amino acids linked by peptide bonds. The working convention is that chains under roughly 50 amino acids are peptides and anything longer is a protein. Insulin sits right at that boundary at 51 amino acids across two chains, which is part of why it gets described both ways depending on who’s talking.
Scale matters more than it sounds. BPC-157 is 15 amino acids, which is why you’ll see it called a pentadecapeptide. Ipamorelin is five. SS-31 is four. MOTS-c is 16. These are small, specific sequences, and that size is exactly what determines how they behave in the body: how fast they clear, whether they survive the gut, and how precisely they bind.
The functional definition is more useful than the length definition. Peptides are signaling molecules. Your body already runs on them. Ghrelin tells your brain you’re hungry. GLP-1 tells your pancreas to release insulin. Growth hormone releasing hormone tells your pituitary to pulse. Therapeutic peptides work by entering conversations your cells are already having, either by mimicking a native signal, extending one, or restoring one that’s declined with age.
How Are Peptides Different From Hormones and From Drugs?
The distinction that trips people up most is peptide versus hormone, because the categories overlap. Plenty of hormones are peptides. Insulin, growth hormone, and GLP-1 all qualify. The difference is functional, not structural: “hormone” describes a job, meaning a molecule secreted by a gland that travels through blood to act somewhere else. “Peptide” describes a structure.
Where it gets clinically important is the difference between replacing a hormone and signaling upstream of one. Injecting synthetic growth hormone replaces the hormone directly and suppresses your own pituitary output through negative feedback. A growth hormone secretagogue like ipamorelin does something different. It prompts your pituitary to release its own growth hormone in a pulse, which means the body’s feedback loops and somatostatin brake still function. That’s a meaningfully different safety and physiology profile, and it’s the entire argument for secretagogues over exogenous hGH.
The contrast with small-molecule drugs is just as important. Most conventional drugs are synthetic compounds designed to block, inhibit, or force a receptor. Statins inhibit an enzyme. Beta blockers occupy a receptor so adrenaline can’t. They work by interference. Peptides tend to work by instruction, binding a receptor the body already built for a molecule it already makes.
Two practical consequences follow. Peptides are generally well tolerated because the body has existing machinery to recognize and degrade them into amino acids. And they’re generally less dramatic in effect than a drug engineered to force a pathway. Anyone promising you a peptide that works like a pharmaceutical hammer is selling something.
What Are the Main Categories of Peptides?
Organizing peptides by what they target is far more useful than organizing them alphabetically. Six categories cover almost everything a beginner will encounter, and knowing which category a compound belongs to tells you roughly what timeline to expect and what to measure.
| Category | Representative Peptides | What It Targets | Time to Notice Change |
|---|---|---|---|
| Repair | BPC-157, TB-500 | Soft tissue, tendon, gut lining, angiogenesis | 2–6 weeks |
| GH secretagogues | Ipamorelin, CJC-1295, sermorelin, tesamorelin | Pituitary GH pulse, IGF-1, body composition | Sleep 1–2 wks; composition 3–6 mo |
| Metabolic | MOTS-c, AOD-9604 | AMPK signaling, insulin sensitivity, fat oxidation | 4–12 weeks |
| Mitochondrial | SS-31 (elamipretide) | Cardiolipin, inner membrane, ATP output | 4–8 weeks |
| Cognitive | Semax, Selank | BDNF expression, serotonin and GABA tone | Days to 3 weeks |
| Immune | Thymosin alpha-1 | T-cell maturation, dendritic cells, TLR signaling | 4–12 weeks |
A few notes on the categories. Repair peptides are the most common entry point, and BPC-157 and TB-500 are frequently paired because they act through different mechanisms: BPC-157 is heavily studied for gut and tendon cytoprotection and angiogenesis, while TB-500 is a synthetic fragment of thymosin beta-4 that binds actin and supports cell migration into injured tissue. Our peptide stacking guide covers how those combinations are actually built.
The growth hormone secretagogue category splits into two mechanisms that are often combined. Sermorelin and CJC-1295 are GHRH analogs acting on the GHRH receptor. Ipamorelin is a ghrelin receptor agonist acting on a separate pathway. Using one from each produces a larger pulse than either alone, which is why the ipamorelin plus CJC-1295 pairing is so common.
The metabolic and mitochondrial categories are the most mechanistically interesting and the most oversold. MOTS-c is encoded in mitochondrial DNA rather than nuclear DNA and activates AMPK, the same energy sensor exercise and metformin engage. SS-31 targets cardiolipin on the inner mitochondrial membrane to improve electron transport efficiency. Both have compelling mechanisms. Neither has the human outcome data of a GLP-1 agonist.
Why Are Almost All Peptides Injected?
Because your digestive system is designed to destroy them. Peptides are made of the same amino acid chains as dietary protein, and your gut cannot tell the difference. Pepsin starts the demolition in the stomach, trypsin and chymotrypsin continue it in the small intestine, and brush-border peptidases finish the job at the intestinal wall. What reaches your bloodstream is free amino acids, not an intact signaling molecule.
The scale of the problem is easy to underestimate. Novo Nordisk spent years engineering an oral semaglutide tablet, pairing it with the absorption enhancer SNAC and requiring it be taken fasted with minimal water. That entire effort still produces only low single-digit percentage bioavailability. Injected semaglutide, by comparison, is essentially fully absorbed. If a pharmaceutical company with that budget lands at 1%, an unformulated oral peptide capsule is not quietly outperforming it.
Subcutaneous injection into fat tissue is the standard route for a reason. It’s simple, uses a tiny insulin syringe, and delivers the peptide intact into circulation with predictable absorption. Intramuscular injection is used occasionally. Nasal sprays are the one real exception worth knowing about, and they work for a narrow group: Semax and Selank are small enough and target the brain, so intranasal delivery is the researched route for both rather than a workaround.
Dr. Nguyen’s Clinical Perspective: I get asked about oral BPC-157 capsules constantly, and the honest answer is that the marketing outran the chemistry. There is real preclinical work on orally administered BPC-157 acting locally on the gut lining, and that’s a legitimate and interesting mechanism. But it is not the same claim as systemic absorption reaching a tendon in your shoulder. Those two things get blended together in product copy all the time. If someone is treating a gut issue, oral has a rationale. If they’re treating a knee, they’re mostly paying for expensive amino acids. After 27 years of compounding, the pattern I see is that the compounds with the loudest oral marketing are usually the ones with the weakest oral data.
How Do You Reconstitute and Store Peptides Correctly?
Peptides ship as a lyophilized powder, meaning freeze-dried, because they’re far more stable dry than in solution. That powder often looks like almost nothing, sometimes just a faint film at the bottom of the vial. That’s normal. A 5 mg peptide vial contains 5 mg of material, which is a barely visible amount.
Reconstitution means adding a sterile diluent to dissolve the powder. Bacteriostatic water, which is sterile water containing 0.9% benzyl alcohol as a preservative, is standard for multi-dose vials because the preservative allows repeated needle entry. Plain sterile water has no preservative and is appropriate only for single use. The concentration you end up with is simply the peptide amount divided by the volume added, so 5 mg of powder in 2 mL of bacteriostatic water yields 2.5 mg/mL.
Storage rules are straightforward. Lyophilized vials are stable at room temperature for short periods and belong in the refrigerator or freezer for long-term holding. Once reconstituted, the vial goes in the refrigerator at 2–8°C and stays out of light. A bacteriostatic-water vial is typically used within about 28 days of first puncture. Never freeze a reconstituted peptide, and never leave one sitting on a warm counter.
Dr. Nguyen’s Clinical Perspective: The three reconstitution mistakes I actually see, in order of frequency. First, people blast the diluent straight down onto the powder cake at full pressure. Aim the stream at the glass wall of the vial and let it run down. Peptides are fragile chains and mechanical shear damages them. Second, people shake the vial like a cocktail. Don’t. Swirl it gently, or set it down and wait a minute, because it will dissolve on its own. Foaming means you’re denaturing product. Third, and this is the expensive one, people reconstitute a vial they won’t finish and then leave it at room temperature. I’ve had patients run a full eight-week protocol on material that lost potency in week two and conclude the peptide doesn’t work. It probably did work. It just wasn’t intact by the time they injected it.
Typical Time to First Noticeable Change, by Peptide Category
Bar length represents the upper end of the typical window. Scale: 0 to 24 weeks.
What Do Realistic Timelines Actually Look Like?
The single most common reason people abandon a peptide protocol is that they quit before the compound had a chance to do anything. Peptides are not stimulants. With the partial exception of the cognitive peptides, you should not expect to feel something on day one, and feeling something on day one is not how you evaluate whether it’s working.
Growth hormone secretagogues are the clearest illustration. Many people notice deeper sleep within the first week or two, because the GH pulse is tied to slow-wave sleep. That early sleep change is real, but it is not the endpoint. Changes in body composition, lean mass, and recovery capacity take three to six months, and they show up on a scale, a tape measure, and an IGF-1 draw rather than as a sensation.
Repair peptides are the opposite pattern. There’s rarely any felt sensation at all, but people report a nagging tendon or gut issue simply being less noticeable somewhere in the two-to-six week window. Metabolic and mitochondrial peptides usually need eight to twelve weeks and are best judged on lab markers, not mood.
Research-Grade Peptides for Laboratory Use
For research-grade peptides at ≥98% purity verified by third-party batch testing, with a published Certificate of Analysis for every lot covering identity, purity, quantitative assay, heavy metals by ICP-MS, and microbial counts, Elite Biologix supplies compounds for qualified research environments: BPC-157, Ipamorelin, and MOTS-c.
How Should You Sequence a First Protocol?
One peptide at a time. This is the rule beginners break most often and the one that costs them the most information. If you start BPC-157 and ipamorelin in the same week and something improves, you’ve learned nothing about which one did it. If something goes wrong, you’ve learned nothing about which one to stop.
A sensible first sequence looks like this. Pick the single most bothersome problem, choose the category that matches it, and run one compound for a full cycle at a consistent dose and time of day. Repair peptides get four to eight weeks. Secretagogues get twelve. Metabolic and mitochondrial compounds get eight to twelve. Then reassess against the specific marker you chose at the start, whether that’s shoulder range of motion, fasting insulin, or sleep tracker deep-sleep minutes.
Pick the marker before you start. Retrospective assessment of a peptide is nearly worthless because expectation shapes recall. Write down the number, the pain score, or the lab value on day zero.
Only after a single compound has been evaluated does stacking make sense, and then only combining across categories rather than within one. Two repair peptides with complementary mechanisms is reasonable. A secretagogue alongside a repair peptide is reasonable. Four new compounds at once is a mess. If you’re already on a GLP-1, the sequencing question is different again, and both our semaglutide guide and the tirzepatide breakdown cover how peptides layer onto incretin therapy.
What Baseline Labs Are Worth Running?
Baseline labs serve two purposes: they tell you whether a peptide is the right tool at all, and they give you a number to compare against later. Without them, you’re evaluating a several-hundred-dollar-per-month protocol on vibes.
The core panel for anyone starting metabolic or growth hormone work: comprehensive metabolic panel, complete blood count, fasting glucose, fasting insulin, HbA1c, a full lipid panel, and IGF-1. Add hs-CRP as a general inflammation marker and a thyroid panel with TSH, free T3, and free T4, since thyroid dysfunction mimics a lot of what people hope peptides will fix.
IGF-1 deserves specific mention. It’s the practical readout for growth hormone secretagogues because GH itself is pulsatile and a random draw tells you almost nothing. IGF-1 is stable enough to trend. Get it before starting and again at eight to twelve weeks, and it becomes the objective measure of whether the compound is doing what it claims.
Get Your Baseline Labs First
Dr. Nguyen recommends baseline labs before starting any peptide protocol. Order at-home through Private MD Labs (code MICHAEL166 for 15% off).
How Strong Is the Evidence, Honestly?
Thinner than the marketing suggests, and thicker than the skeptics claim. Both halves of that sentence matter, and the honest position requires holding them at the same time.
Start with what’s real. The mechanistic work on most of these compounds is substantial and published in mainstream journals. BPC-157’s cytoprotective and angiogenic effects have been characterized across dozens of animal studies. MOTS-c’s identification as a mitochondrially encoded peptide activating AMPK was published in Cell. SS-31’s binding to cardiolipin and its effect on electron transport efficiency is well described. Thymosin alpha-1 is not experimental at all in much of the world; it’s an approved immunomodulator in a number of countries. These are not invented molecules.
Now the gap. For most of these peptides, large randomized human trials do not exist. Part of that is a genuine funding artifact. Many of these sequences are unpatentable or commercially unattractive, and nobody spends $200 million on a phase 3 program for a molecule they can’t own. The absence of a trial is not evidence the compound fails. It’s frequently evidence that nobody stood to profit from finding out.
But that argument gets abused, and it does not cover every case. The cleanest example is elamipretide (SS-31), the mitochondrial peptide with one of the most elegant mechanisms in the category. It has been through real randomized human testing, and in the MMPOWER trial in adults with primary mitochondrial myopathy the highest dose improved six-minute walk distance by 64.5 m versus 20.4 m for placebo — a difference that did not reach statistical significance at p = 0.053 (Karaa et al., Neurology, 2018, PMID: 29500292). That is not a funding gap. That is a trial that ran and landed just short, and no amount of mechanistic elegance rewrites the number. AOD-9604 is the other one beginners should know: a growth hormone fragment with striking fat-loss results in obese rodents whose human obesity development did not go on to produce a convincing weight-loss result or an approved product. When someone tells you a peptide is only unproven because nobody funded the trial, check first whether a trial actually ran.
The workable position: treat strong mechanism plus absent trials as promising and worth a monitored personal trial with objective markers. Treat strong mechanism plus a failed trial as a closed question for that specific indication. And be suspicious of any source that applies the first framing to compounds that belong in the second.
Frequently Asked Questions
Are peptides safe for beginners?
Most peptides have favorable tolerability profiles because the body degrades them into ordinary amino acids using machinery it already has. The larger safety variable is usually product quality and sterile technique, not the molecule. Growth hormone secretagogues warrant more caution than repair peptides because they raise IGF-1, which is why baseline and follow-up IGF-1 testing matters. Anyone with an active cancer history should not be raising IGF-1 without oncology input.
Do I have to inject peptides, or can I take them orally?
For systemic effect, almost always injection. Digestive enzymes break peptides into amino acids before absorption, which is why oral semaglutide needed a purpose-built absorption enhancer just to reach about 1% bioavailability. The exceptions are narrow: intranasal delivery is the researched route for Semax and Selank, and oral BPC-157 has a plausible local rationale for gut tissue specifically, not for a distant joint.
How long should a first peptide cycle last?
It depends on category. Repair peptides are typically run four to eight weeks. Metabolic and mitochondrial compounds need eight to twelve weeks before a fair assessment. Growth hormone secretagogues need a full twelve weeks minimum, because sleep changes appear early but body composition changes take three to six months. Choose your assessment marker before day one, and don’t judge the cycle before it’s finished.
Can peptides be combined with GLP-1 medications like semaglutide?
Yes, and it’s one of the more common functional medicine combinations. The usual rationale is that peptides address mechanisms the GLP-1 doesn’t touch, such as gut tolerability during titration or preserving lean mass during rapid weight loss. The sequencing rule still applies: get stable on the GLP-1 first, then add one peptide, so you can attribute any change correctly.
What is bacteriostatic water, and can I use regular sterile water instead?
Bacteriostatic water is sterile water containing 0.9% benzyl alcohol, a preservative that inhibits bacterial growth and allows a vial to be entered with a needle repeatedly. Plain sterile water contains no preservative, so it’s appropriate only for a vial used in a single sitting. For any multi-dose peptide vial, bacteriostatic water is the correct diluent, and the reconstituted vial is generally used within about 28 days.
Conclusion
Peptide therapy makes far more sense once you stop thinking of it as a category of drugs and start thinking of it as a category of signals. That single reframe explains almost everything: why the effects are subtler than a pharmaceutical, why they take weeks rather than days, why they have to be injected, and why the honest evidence picture is a patchwork of strong mechanism and thin human outcome data.
If you take four things from this guide, take these. Run one compound at a time. Get baseline labs and pick your marker before day one. Reconstitute gently and refrigerate. And hold the evidence honestly in both directions, treating missing trials as a funding gap worth investigating personally, while accepting that a trial which ran and failed has answered its question.
Where to Go From Here
For research-grade peptides at ≥98% purity verified by third-party batch testing, with a published Certificate of Analysis per lot, Elite Biologix supplies BPC-157, Ipamorelin, and MOTS-c for qualified research environments.
Want physician-supervised peptide therapy? Metabolic Regen MD offers compounded peptides under licensed provider oversight.
References
- Sikiric P, Seiwerth S, Rucman R, et al. “Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract.” Current Pharmaceutical Design. 2011;17(16):1612-32. PMID: 21548867
- Staresinic M, Sebecic B, Patrlj L, et al. “Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth.” Journal of Orthopaedic Research. 2003;21(6):976-83. PMID: 14554208
- Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JS. “The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration.” Journal of Applied Physiology. 2011;110(3):774-80. PMID: 21030672
- Goldstein AL, Hannappel E, Kleinman HK. “Thymosin beta-4: actin-sequestering protein moonlights to repair injured tissues.” Trends in Molecular Medicine. 2005;11(9):421-9. PMID: 16099219
- Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. “Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.” Journal of Clinical Endocrinology & Metabolism. 2006;91(3):799-805. PMID: 16352683
- Sigalos JT, Pastuszak AW. “The safety and efficacy of growth hormone secretagogues.” Sexual Medicine Reviews. 2018;6(1):45-53. PMID: 28400207
- Lee C, Zeng J, Drew BG, et al. “The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance.” Cell Metabolism. 2015;21(3):443-54. PMID: 25738459
- Birk AV, Liu S, Soong Y, et al. “The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin.” Journal of the American Society of Nephrology. 2013;24(8):1250-61. PMID: 23813215
- Karaa A, Haas R, Goldstein A, Vockley J, Weaver WD, Cohen BH. “Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy.” Neurology. 2018;90(14):e1212-e1221. PMID: 29500292
- Wilding JPH, Batterham RL, Calanna S, et al. “Once-weekly semaglutide in adults with overweight or obesity.” New England Journal of Medicine. 2021;384(11):989-1002. PMID: 33567185
- Drucker DJ. “Mechanisms of action and therapeutic application of glucagon-like peptide-1.” Cell Metabolism. 2018;27(4):740-756. PMID: 29617641
This article is for educational and informational purposes only and does not constitute medical advice. Most peptides discussed here are not FDA-approved for the uses described. Individual results vary.